BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Treatment
26670 results:

  • 1. Combination Effect of Deferoxamine and Arsenic Trioxide on Viability and Vitality of APL Like Cell Line.
    Ghaffari K; Bayat A; Ghasemi A
    Ethiop J Health Sci; 2023 Jul; 33(4):703-710. PubMed ID: 38784214
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Low subcutaneous adipose tissue and myosteatosis are prognostic factors after allogeneic hematopoietic stem cell transplantation.
    Barajas Ordonez F; Zeller Y; Wolleschak D; Hinnerichs M; Rodríguez-Feria P; Mougiakakos D; Aghayev A; Kardas H; Mikusko M; Borggrefe J; Surov A
    Clin Nutr ESPEN; 2024 Jun; 61():274-280. PubMed ID: 38777443
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. treatment intensity affects immune reconstitution even after childhood cancer not treated with hematopoietic stem cell transplantation.
    Antikainen E; Grönroos M; Huurre A; Korhonen L; Peltola V; Lähteenmäki P; Schuez-Havupalo L
    Cancer Rep (Hoboken); 2024 May; 7(5):e2069. PubMed ID: 38767518
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Fertility preservation in female cancer patients in Brazil: perceptions and attitudes of infertility specialists.
    Ranniger RL; Lamaita RM; D'Abreu BF; Tolentino MR; Cândido EB; Andrade WP; Nogueira-Rodrigues A; Silva-Filho AL
    Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765513
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation.
    Zhou F; Du F; Wang Z; Xue M; Wu D; Chen S; He X
    J Hematol Oncol; 2024 May; 17(1):34. PubMed ID: 38764055
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Impact of Fee For Service on the Efficiency and Survival of Seguro Popular's Patients With Acute Lymphoblastic leukemia in Mexico.
    Cerecero-García D; Macías-González F; Muñoz-Aguirre P; Huerta-Gutierrez R; Zapata M; Rivera-Luna R; Lajous M; Bautista-Arredondo S
    JCO Glob Oncol; 2024 May; 10():e2300060. PubMed ID: 38754053
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pharmacogenomics, Race, and treatment Outcome in Pediatric Acute Myeloid leukemia.
    Lamba JK; Marrero R; Wu H; Cao X; Parcha PK; Karol SE; Inaba H; Kuo DJ; Degar BA; Heym K; Taub JW; Lacayo NJ; Pui CH; Ribeiro RC; Pounds SB; Rubnitz JE
    JAMA Netw Open; 2024 May; 7(5):e2411726. PubMed ID: 38753328
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
    Xin F; Yu YH; Shen XL; Zhang GX
    Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
    Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later.
    Max RN; Daniela SB; Moisés M GP; Edgar J HF; Merittzel A MR; María de L PM; Juan C OG; Guillermo J RD; Guillermo J RA
    Rev Invest Clin; 2024; 76(2):91-96. PubMed ID: 38740380
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers.
    Georgievski A; Bellaye PS; Tournier B; Choubley H; Pais de Barros JP; Herbst M; Béduneau A; Callier P; Collin B; Végran F; Ballerini P; Garrido C; Quéré R
    Cell Death Dis; 2024 May; 15(5):328. PubMed ID: 38734740
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in leukemia and Lymphoma Cells In Vitro.
    Wilke N; Frias C; Berkessel A; Prokop A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731935
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Systems Biology for Drug Target Discovery in Acute Myeloid leukemia.
    Novikova S; Tolstova T; Kurbatov L; Farafonova T; Tikhonova O; Soloveva N; Rusanov A; Zgoda V
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731835
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Efficacy of surgical treatment of perianal infection in patients with hematological malignancy.
    He J; Ni Z; Li Z
    Medicine (Baltimore); 2024 May; 103(19):e38082. PubMed ID: 38728504
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
    Gregorio C; Spreafico M; D'Amico S; Sauta E; Asti G; Lanino L; Tentori CA; Platzbecker U; Haferlach T; Diez-Campelo M; Fenaux P; Komrokji R; Della Porta MG; Ieva F
    JCO Clin Cancer Inform; 2024 May; 8():e2300205. PubMed ID: 38723213
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
    Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
    [No Abstract]    [Full Text] [Related]  

  • 17. [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].
    Xiao QQ; Yu XL; Song XC; Hou YX; Deng L; Li WJ; Zhou F
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):249-256. PubMed ID: 38716596
    [No Abstract]    [Full Text] [Related]  

  • 18. [treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
    Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
    [No Abstract]    [Full Text] [Related]  

  • 19. JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid leukemia Treated with Imatinib.
    Wijaya I; Bashari MH; Reniarti L; Rahmawati A; Roesli RMA
    Dis Markers; 2024; 2024():2906566. PubMed ID: 38716474
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1334.